Robert C. Chick
Immunology and Microbiology · The Ohio State University
Publications
68
Citations
1,637
Est. group size
—
Recurring co-author estimate
Active years
12
Publishing since 2014
Robert C. Chick's work focuses on surgical oncology, particularly cancer immunotherapy, vaccine development, and treatment strategies for melanoma, pancreatic cancer, and other gastrointestinal cancers. His research includes clinical trials of cancer vaccines and drug therapies, as well as studies comparing surgical approaches and outcomes for tumors of the pancreas, liver, and colon. This work is largely clinical and translational, bridging laboratory-based immune therapies with real-world patient treatment and surgical decision-making.
Publication output increased sharply starting around 2020 after minimal activity in prior years, then has shown a somewhat variable but generally active pace over the past five years, averaging about 7 publications per year.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Adoptive T-Cell Therapy in Melanoma
Surgical Oncology Clinics of North America · 2025
- Risk of peritoneal metastasis following minimally invasive colectomy for locally advanced colon cancer: a systematic review and meta-analysis.
PubMed · 2025
- Biliary Cancers
2025
- Open vs robotic-assisted pancreaticoduodenectomy, cost-effectiveness and long-term oncologic outcomes: a systematic review and meta-analysis
Journal of Gastrointestinal Surgery · 2024
- Updates in Immunotherapy for Pancreatic Cancer
Journal of Clinical Medicine · 2024
- Implementation of Hepatic Artery Infusion Pump Therapy: Real‐World Single‐Center Experience
Journal of Surgical Oncology · 2024
- Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial
Cancer Treatment and Research Communications · 2024
- Factors associated with prognosis and staging of intrahepatic cholangiocarcinoma
Journal of Cancer Metastasis and Treatment · 2024
- Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-Loaded, Dendritic Cell Vaccine (TLPLDC) to Prevent Recurrence in Resected Stage III/IV Melanoma Patients: Results of a Phase I/IIa Trial
Research Square · 2024
- Upregulation of GREB1 in colorectal cancer ovarian metastases may be a potential therapeutic target.
Journal of Clinical Oncology · 2024
- Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
Journal for ImmunoTherapy of Cancer · 2023
- Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results
Cancers · 2023
- Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters
Journal of Surgical Oncology · 2023
- Data from Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression
2023
- Supplemental File 2 from Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression
2023
- Journal of Clinical Oncology×5
- Annals of Surgical Oncology×4
- Regular and Young Investigator Award Abstracts×4
- HPB×3
- Journal of surgical education×2
- Elaine R. Mardis
Immunology and Microbiology · The Ohio State University
- Diana M. Lopez
Immunology and Microbiology · The Ohio State University
- Aki Hoji
Immunology and Microbiology · Indiana University
- Athanasios Papadas
Immunology and Microbiology · The Ohio State University
- Elizabeth A.R. Garfinkle
Immunology and Microbiology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile